Table 1.
Clinical data.
| HSP | LSP | |
|---|---|---|
| Total (Dead) | 47 (24) | 31 (3) |
| Mean Age ± SD | 46.5 ± 17 | 48.5 ± 14.3 |
| Males Mean age ± SD | 16 (9) | 15 (2) |
| 46 ± 14.6 | 52.9 ± 11 | |
| Females Mean age ± SD | 31 (15) | 16 (1) |
| 46.8 ± 18.3 | 44.3 ± 16.1 | |
| High Proliferation | 22 (15) | 4 (2) |
| Tumor Stage | ||
| Stage I | 3 (1) | 6 (0) |
| Stage II | 18 (6) | 19 (1) |
| Stage III | 12 (6) | 4 (1) |
| Stage IV | 12 (10) | 2 (1) |
| Hormone Excess | ||
| Cortisol | 27 (14) | 5 (1) |
| Mineralocorticoids | 3 (1) | 1 (0) |
| Sexual | 20 (14) | 8 (1) |
| Immune Subtype | ||
| C1 | 1 (1) | 0 (0) |
| C2 | 0 (0) | 1 (1) |
| C3 | 7 (3) | 16 (0) |
| C4 | 37 (19) | 12 (1) |
| C5 | 2 (1) | 1 (0) |
| C6 | 0 (0) | 1 (1) |
The total number of patients for each clinical category for the Low Steroid Phenotype (LSP) and High Steroid Phenotype (HSP) is shown with the number of dead patients in parenthesis. The mean age of participants with the standard deviation (SD) is shown for both groups and subdivided into males and females. All clinical data were retrieved from Zheng et al. (5) and the immune subtype classification from Thorsson et al. (11). Proliferation is bipartite as presented by Zheng et al. (5) based on transcriptomic classification and associated with markers such KI67 and BUB1.